A Third Look: Discussing the 2023 AACR presentation of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma (HNSCC)

Executed on:Feb 15, 2024 10:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Vall d'Hebron Institute of OncologyClinician scientist in the Vall d'Hebron Barcelona Hospital Campus and Institute of Oncology.
Involved with Phase 1 Clinical Trials Unit with a special focus on Head and Neck Cancer.
Research interests include the development of novel predictive biomarkers for targeted therapies and immunotherapies to expand precision oncology across head and neck and rare cancers.

Interview Goal

Discuss petosemtamab potential in monotherapy and in combo with Keytruda in HSNCC

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.